高频胸壁振荡在伴支气管高分泌的急性呼吸衰竭中的应用:一项随机对照试验
本研究为单中心随机对照试验,纳入88例在呼吸重症监护室(RICU)接受无创呼吸支持(经鼻高流量氧疗和/或无创通气)、存在支气管高分泌且咳嗽无效(峰咳嗽呼气流速<270 L/min)的急性呼吸衰竭患者,1:1随机接受高频胸壁振荡联合标准治疗或单纯标准治疗。主要终点为治疗性支气管镜需求:高频胸壁振荡组6例(13.6%)vs 对照组14例(31.8%),未校正p=0.042,但校正年龄、性别和主要住院原因后未达统计学显著(校正OR 0.336,95%CI 0.111-1.021;p=0.055)。次要终点(未校正多重比较,属探索性)显示住院时间(12[10-15.5]天 vs 16.5[13-21]天)和RICU停留时间(8[7-10.5]天 vs 12[9-17]天)缩短,校正后分别减少4.5天和3.6天;经鼻高流量氧疗时间缩短(6[4-8]天 vs 9.5[6-11.5]天)且校正后仍显著,而无创通气时间缩短校正后不显著(校正p=0.166)。无患者需要气管插管,死亡率无差异。作者认为该探索性试验中高频胸壁振荡未显著减少治疗性支气管镜需求,住院时间和经鼻高流量氧疗时间的缩短属假设生成性,需在足够把握度的多中心试验中确认。
要点
- 在需要无创呼吸支持的急性呼吸衰竭伴支气管高分泌和咳嗽无效(峰咳嗽呼气流速<270 L/min)患者中,高频胸壁振荡组治疗性支气管镜需求6例(13.6%)vs 对照组14例(31.8%),未校正p=0.042,但校正后未达统计学显著(校正OR 0.336,95%CI 0.111-1.021;p=0.055)。
- 高频胸壁振荡组住院时间12[10-15.5]天 vs 对照组16.5[13-21]天,校正后减少4.5天;RICU停留时间8[7-10.5]天 vs 12[9-17]天,校正后减少3.6天;次要终点未校正多重比较,属探索性。
- 经鼻高流量氧疗时间高频胸壁振荡组6[4-8]天 vs 对照组9.5[6-11.5]天,校正后仍显著;无创通气时间缩短校正后不显著(校正p=0.166)。
- 两组均无患者需要气管插管,死亡率无差异。
- 作者认为住院时间和经鼻高流量氧疗时间的缩短属假设生成性,需在足够把握度的多中心试验中确认。
适用人群与场景
- 在呼吸重症监护室(RICU)接受无创呼吸支持(经鼻高流量氧疗和/或无创通气)的急性呼吸衰竭患者,且存在支气管高分泌和咳嗽无效(峰咳嗽呼气流速<270 L/min)。
诊断标准与关键阈值
- 咳嗽无效定义为峰咳嗽呼气流速<270 L/min。
研究设计与关键结果
- 单中心随机对照试验,纳入88例患者(高频胸壁振荡组44例,对照组44例),基线特征可比。
- 主要终点治疗性支气管镜需求:高频胸壁振荡组6例(13.6%)vs 对照组14例(31.8%),未校正p=0.042;校正年龄、性别和主要住院原因后未达统计学显著(校正OR 0.336,95%CI 0.111-1.021;p=0.055)。
- 住院时间:高频胸壁振荡组12[10-15.5]天 vs 对照组16.5[13-21]天,校正后减少4.5天;RICU停留时间:8[7-10.5]天 vs 12[9-17]天,校正后减少3.6天;次要终点未校正多重比较,属探索性。
- 经鼻高流量氧疗时间:高频胸壁振荡组6[4-8]天 vs 对照组9.5[6-11.5]天,校正后仍显著;无创通气时间缩短校正后不显著(校正p=0.166)。
- 无患者需要气管插管,死亡率无差异。
证据类型、等级与局限
- 研究类型:单中心随机对照试验(探索性)。
- 局限:作者指出该试验为探索性,住院时间和经鼻高流量氧疗时间的缩短属假设生成性,需在足够把握度的多中心试验中确认。
对床旁实践的改变
- 作者认为,在需要无创呼吸支持的急性呼吸衰竭伴支气管高分泌和咳嗽无效的患者中,高频胸壁振荡未显著减少治疗性支气管镜需求(校正后),住院时间和经鼻高流量氧疗时间的缩短属假设生成性,需在足够把握度的多中心试验中确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Airway secretion retention is common in patients with acute respiratory failure (ARF), particularly in those requiring noninvasive respiratory support (NIRS). High-frequency chest wall oscillation (HFCWO) may improve airway clearance but critical care evidence remains limited.
RESEARCH QUESTION: Does adding HFCWO to standard care improve clinical outcomes in patients with bronchial hypersecretion and ARF requiring NIRS?
STUDY DESIGN AND METHODS: We conducted a single-center randomized controlled trial in a RICU. Patients with ARF requiring NIRS, including high-flow nasal cannula (HFNC) and/or noninvasive ventilation (NIV), bronchial hypersecretion, and ineffective cough (peak cough expiratory flow <270 L/min) were randomized 1:1 to HFCWO plus standard care or standard care alone. The primary endpoint was therapeutic bronchoscopy. Secondary endpoints included hospital length of stay (LOS), RICU-LOS, NIRS duration, endotracheal intubation and mortality. Outcomes were analyzed using unadjusted and adjusted models accounting for age, sex, and main cause of hospitalization.
RESULTS: Eighty-eight patients were enrolled (44 HFCWO, 44 control), with comparable baseline characteristics. Bronchoscopy was required in 6 patients (13.6%) versus 14 (31.8%) (unadjusted p=0.042); after adjustment the association did not retain statistical significance (adjusted OR 0.336, 95% CI 0.111-1.021; p=0.055). Secondary outcomes, analyzed without correction for multiple testing, are exploratory. Hospital stay (12 [10-15.5] vs 16.5 [13-21] days) and RICU stay (8 [7-10.5] vs 12 [9-17] days) were shorter, with adjusted reductions of 4.5 and 3.6 days. HFNC duration was shorter (6 [4-8] vs 9.5 [6-11.5] days) and remained significant after adjustment, whereas the reduction in NIV duration did not (adjusted p=0.166). No patient required intubation and mortality did not differ.
INTERPRETATION: In this exploratory trial, HFCWO did not significantly reduce the need for therapeutic bronchoscopy after adjustment. Associated reductions in LOS and HFNC duration are hypothesis-generating and require confirmation in adequately powered multicenter trials.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT05751707; Tuscany Ethics Committee (Protocol: 21987-10/17/2022).
参考来源
- Ielo S, Golfi N, Guidelli L, et al. High-Frequency Chest Wall Oscillation in Acute Respiratory Failure With Bronchial Hypersecretion: A Randomized Controlled Trial. Chest. 2026. PMID: 42874912. doi:10.1016/j.chest.2026.10.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。